Access to psychedelic-assisted therapies, including with methylenedioxymethamphetamine (MDMA), for people suffering from post-traumatic stress disorder (PTSD) in the US

In 2023, approximately 60 million people in the United States were diagnosed with mental illness, including PTSD; this represents an increase from 2020. Forty to sixty percent of patients do not respond to the Food and Drug Administration’s (FDA’s) approved first-line therapies for the treatment of PTSD. Mental health conditions are also common for people with cancer. Frustration with the existing mental health therapies prompted researchers to investigate psychedelic-assisted therapies (PATs). Recent studies have shown that PATs significantly reduce mental health symptoms of clinical trial participants and promise to help tackle a range of conditions, including Major Depressive Disorder and PTSD. The FDA did not approve MDMA-assisted therapies in August 2024 and requested an additional Phase 3 clinical trial. Meanwhile, states such as Oregon and Colorado are implementing PAT programs. As the FDA and states slowly consider the approval of PATs, questions of cost and access have surfaced. This study examined barriers and facilitators to accessing PAT and their implications for cancer patients; it also showcased the challenges and opportunities of the PAT philanthropic ecosystem. The study concluded that integrating PAT into the U.S. healthcare system could transform mental health treatment, including for cancer patients. However, improving access will require a multi-pronged approach to facilitate approvals, increase affordability, and raise awareness of PAT’s potential benefits and risks. PAT regulatory changes should be coupled with a clear path for insurance reimbursement and more federal support and programming, including through Medicaid. A growing body of data has shown that PATs are also a great tool to address cancer-related distress (CRD). Better public awareness programs would support patients receiving PAT, including cancer patients. Additionally, the study highlighted the need for PAT funders to communicate more transparently about the rationale behind their funding decisions. There is also a call for greater collaboration among funders supporting PATs and those involved in broader drug policy initiatives.PAT's possible integration into the U.S. healthcare system represents a transformative opportunity for mental health. PATs have the potential to facilitate profound healing for individuals and their communities. Improving access, particularly for uninsured patients, is critical for achieving this promise.